Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAbraira del Fresno, Laura
dc.contributor.authorSalas Puig, Xavier
dc.contributor.authorQuintana Luque, Manuel
dc.contributor.authorSeijo Raposo, Ivan Manuel
dc.contributor.authorSantamarina Pérez, Estevo
dc.contributor.authorFonseca Hernandez, Elena
dc.contributor.authorToledo Argany, Manuel
dc.date.accessioned2022-05-24T06:57:29Z
dc.date.available2022-05-24T06:57:29Z
dc.date.issued2021
dc.identifier.citationAbraira L, Salas-Puig J, Quintana M, Seijo-Raposo IM, Santamarina E, Fonseca E, et al. Overnight switch from levetiracetam to brivaracetam: safety and tolerability. Epilepsy Behav Reports. 2021;16:100504.
dc.identifier.issn2589-9864
dc.identifier.urihttp://hdl.handle.net/11351/7571
dc.descriptionBrivaracetam; Epilepsy; Tolerability
dc.description.abstractBrivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight switch from levetiracetam to brivaracetam. This was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (AEs). In total, forty-one patients were included (mean age 40.9 ± 17.8 years, women 48.8%). Focal epilepsy represented 75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). Four patients had idiopathic generalized epilepsy, two had developmental and epileptic encephalopathy and four patients were unclassified. The reason to start brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were reported in 24.4%. Neuropsychological AEs associated with the previous use of levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% patients. Patients’ reported seizure frequency improved, worsened and remained stable in 26.8%, 12.2%, and 61.0% of the cases, respectively. An overnight switching to brivaracetam is safe and well tolerated. This treatment can improve levetiracetam-related neuropsychiatric AEs.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEpilepsy & Behavior Reports;16
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAnticonvulsius - Ús terapèutic
dc.subjectEpilèpsia - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshAnticonvulsants
dc.subject.mesh/administration & dosage
dc.subject.meshTreatment Outcome
dc.subject.meshEpilepsy
dc.titleOvernight switch from levetiracetam to brivaracetam: safety and tolerability
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ebr.2021.100504
dc.subject.decsanticonvulsivantes
dc.subject.decs/administración & dosificación
dc.subject.decsresultado del tratamiento
dc.subject.decsepilepsia
dc.relation.publishversionhttps://doi.org/10.1016/j.ebr.2021.100504
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliationUnitat d’Epilèpsia, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34901817
dc.identifier.wos000730415800003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record